Geographic Atrophy Secondary to Age-related Macular Degeneration research hub
11 indexed studies · 6 currently recruiting
- recruitingPHASE1, PHASE2
An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)
This study, called Opti-GAIN, is testing a new treatment called CTx001 for a type of vision loss called geographic atrophy (GA), which is caused by age-related macular degeneration (AMD). We want to see if CTx001 is safe and if it helps improve or slow down GA.
United States · United Kingdom - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Multicentre, Randomised, Double-masked, Placebo-controlled, Parallel-group, Dose-range Finding Study, to Assess the Efficacy and Safety of Oral STL303 in Adults with Geographic Atrophy Secondary to Age-related Macular Degeneration
This study is testing an experimental capsule called STL303 for geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Researchers want to see if taking this medicine by mouth can protect light-sensing cells at the back of the eye and safely slow down vision loss over two years.
Poland · Czechia - authorisedTherapeutic exploratory (Phase II)
An open-label multiple dose safety, tolerability and exploratory efficacy clinical trial of PST-611 in patients with geographic atrophy secondary to age-related macular degeneration
This phase 2 clinical trial is testing a new study drug called PST-611 for people with geographic atrophy, an advanced form of dry age-related macular degeneration (AMD). Researchers want to find out whether repeated doses of the medicine are safe, well tolerated, and able to protect sight.
France - recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Pegcetacoplan in Subjects with Geographic Atrophy Secondary to Age-Related Macular Degeneration
This study looks at the long-term effects of a treatment called pegcetacoplan, also known as APL-2, for people with a common eye condition called Geographic Atrophy. Researchers want to see if it's safe and helps slow down vision loss over time.
Spain · Netherlands · Italy - completedPhase II
A long-term extension study of JNJ-81201887 (AAVCAGsCD59) parent studies in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD)
This study looks at the long-term safety of a new gene therapy, JNJ-81201887, for Geographic Atrophy (GA), a severe eye condition. It involves people who previously took part in earlier studies of this treatment, to see how they are doing over several years.
United Kingdom · Australia · Belgium - recruiting
A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
This study looks at how a common eye condition called Geographic Atrophy (GA) progresses in older adults. Researchers want to understand changes in vision and eye structure over a short time, and see if these are linked to genes or lifestyle.
United States · United Kingdom - recruitingPHASE2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
This study is testing a new medicine, FWY003, for an eye condition called Geographic Atrophy (GA), which is a severe form of Age-related Macular Degeneration (AMD). We want to see how well different doses of FWY003 work and if they are safe compared to a dummy medicine (placebo).
United States · Argentina · Australia - authorisedTherapeutic exploratory (Phase II)
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
This study is looking at a new treatment called FWY003 for a common eye condition called geographic atrophy. Researchers want to see if FWY003 can slow down the growth of 'blind spots' in the eye and if it's safe to use. Different doses of the treatment are being tested.
Bulgaria · Romania · Germany - recruitingPHASE2
Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
This study is looking at a new treatment called ADX-038 for 'geographic atrophy', a common eye condition that can cause blurry vision. We want to see if ADX-038 works better than a dummy treatment to slow down the condition, and if it's safe.
United States · Australia · Austria - recruitingNA
Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
This study is looking at a new treatment called i-Lumen AMD, which uses a gentle electric current to help people with a common eye condition called Age-related Macular Degeneration (AMD). The aim is to see if it's safe and effective for slowing down the problem in the eyes.
United States · Australia · New Zealand - authorisedTherapeutic exploratory (Phase II)
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
This study is looking at a new treatment called ADX-038 for a serious eye condition called geographic atrophy (GA), which is a late form of age-related macular degeneration (AMD). Researchers want to see if this treatment can slow down the growth of GA.
Germany · Portugal · Italy